UBM Medica US announces that Neurology Times, a leading online community and information resource for neurologists and other healthcare providers, is featuring special coverage of multiple sclerosis in observance of MS Awareness Month.
MS affects 2.5 million persons worldwide, including more than 400,000 Americans, and is the most common disabling neurologic disease of young adults. There is no cure or clear way to prevent MS, but researchers are continually seeking the causes and more therapeutic options.
Among the highlights of MS coverage at Neurology Times are these recent research findings:
- 3 New Things About MS. Coffee intake may protect against MS, women with MS may consume lower amounts of antioxidant and anti-inflammatory nutrients, and identifying MS' pathological progression may lead to new treatment options.
- Double Duty: Blood Pressure Drug Also Eases MS: Guanabenz, an FDA-approved drug for high blood pressure, prevents myelin loss and alleviates clinical symptoms of MS in mice. The findings point to promising avenues for new therapeutics for MS in humans.
- Stem Cells Top Drug Therapy in Severe MS: Intense immunosuppression followed by autologous hematopoietic stem cell transplantation may be superior to current treatment for patients with severe MS that is not responding well to standard treatments.
- Stratifying PML Risk in Multiple Sclerosis: These study findings will help clinicians faced with the difficult choice about how to manage patients with MS on Tysabri who become positive for JC virus antibodies or are already positive for these antibodies.
Health literacy gaps fuel unrealistic antibiotic expectations in primary care patients